{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:16:35Z","timestamp":1754194595534,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Studies comparing self-collected vaginal samples with clinician-collected cervical samples with respect to high-risk human papillomavirus (HPV) detection and genotype agreement based on clinically validated full HPV genotype assays (e.g. the CLART HPV4S) are limited. This study compared the two types of samples using the CLART assay with respect to HPV detection and genotype agreement in a referral population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 212 women aged 30\u201359\u00a0years and diagnosed with atypical squamous cells of undetermined significance (ASC-US) within the Danish cervical cancer screening programme had a cervical sample taken at their general practitioner. Afterwards, the women took a vaginal sample with the Evalyn Brush device at home. The paired samples were HPV-tested with the full genotyping CLART HPV4S assay. Histological results, i.e. cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) were available for 14 women with HPV-positive clinician-collected samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study found the same HPV prevalence in self-collected vaginal samples compared to clinician-collected cervical samples (19.3%, 95% CI 14.3\u201325.3% vs 18.4%, 95% CI 13.4\u201324.3%). The CLART HPV4S assay detected approximately the same number of CIN2+ cases in the self-collected vaginal samples compared to the clinician-collected cervical samples (13 vs 11 cases). Exactly the same genotypes were detected in 75% (21\/28) of the HPV-positive paired samples, while at least one identical genotype was found in the remaining 25% (7\/28) of the paired samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The CLART HPV4S assay performed similarly well in self-collected vaginal samples as in clinician-collected cervical samples with respect to both HPV detection and genotype agreement when using the Evalyn Brush and the CLART HPV4S assay in a referral population. Although further evaluation is needed, the findings suggest that full HPV genotyping based on the CLART assay can be useful when establishing HPV genotype-specific referral strategies for women tested HPV-positive by self-sampling.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-023-02215-4","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:56:02Z","timestamp":1677135362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does full HPV genotyping perform similarly well in clinician-collected cervical samples and self-collected vaginal samples when using the CLART HPV4S assay?"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-0519","authenticated-orcid":false,"given":"Jannie Villekj\u00e6r","family":"Soln\u00e6s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-4176","authenticated-orcid":false,"given":"Sisse Helle","family":"Njor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-6694","authenticated-orcid":false,"given":"Mette","family":"Tranberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2215_CR1","doi-asserted-by":"publisher","first-page":"k4823","DOI":"10.1136\/bmj.k4823","volume":"363","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta- analyses. BMJ. 2018;363:k4823.","journal-title":"BMJ"},{"issue":"1","key":"2215_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12885-018-4165-4","volume":"18","author":"M Tranberg","year":"2018","unstructured":"Tranberg M, Bech BH, Blaak\u00e6r J, Jensen JS, Svanholm H, Andersen B. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures\u2014a randomized controlled trial. BMC Cancer. 2018;18(1):273.","journal-title":"BMC Cancer"},{"issue":"2","key":"2215_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1470-2045(13)70570-9","volume":"15","author":"M Arbyn","year":"2014","unstructured":"Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172\u201383.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2215_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","volume":"26","author":"PJ Maver","year":"2020","unstructured":"Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579\u201383.","journal-title":"Clin Microbiol Infect"},{"key":"2215_CR5","doi-asserted-by":"publisher","first-page":"104375","DOI":"10.1016\/j.jcv.2020.104375","volume":"127","author":"M Saville","year":"2020","unstructured":"Saville M, Hawkes D, Keung M, Ip E, Silvers J, Sultana F, et al. Analytical performance of HPV assays on vaginal self-collected vs practitioner-collected cervical samples: the SCoPE study. J Clin Virol. 2020;127:104375.","journal-title":"J Clin Virol"},{"issue":"4","key":"2215_CR6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/ijc.32291","volume":"145","author":"J Bonde","year":"2019","unstructured":"Bonde J, Bottari F, Parvu V, Pedersen H, Yanson K, Iacobone AD, et al. Bayesian analysis of baseline risk of CIN2 and \u2265CIN3 by HPV genotype in a European referral cohort. Int J Cancer. 2019;145(4):1033\u201341.","journal-title":"Int J Cancer"},{"issue":"5","key":"2215_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdt538","volume":"25","author":"MG Dijkstra","year":"2014","unstructured":"Dijkstra MG, Snijders PJ, Arbyn M, Rijkaart DC, Berkhof J, Meijer CJ. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol. 2014;25(5):927\u201335.","journal-title":"Ann Oncol"},{"issue":"13","key":"2215_CR8","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/1471-0528.16352","volume":"127","author":"DL Loopik","year":"2020","unstructured":"Loopik DL, Melchers W, Vedder J, van den Brule A, Massuger L, Bekkers R, et al. Reflex cytology for triage of high-risk human papillomavirus positive self-sampled material in cervical cancer screening: a prospective cohort study. BJOG. 2020;127(13):1656\u201363.","journal-title":"BJOG"},{"issue":"Pt B","key":"2215_CR9","first-page":"1","volume":"100","author":"Biological agents","year":"2012","unstructured":"Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1\u2013441.","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"issue":"1","key":"2215_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/LGT.0000000000000494","volume":"24","author":"JH Bonde","year":"2020","unstructured":"Bonde JH, Sandri MT, Gary DS, Andrews JC. Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review. J Low Genit Tract Dis. 2020;24(1):1\u201313.","journal-title":"J Low Genit Tract Dis"},{"key":"2215_CR11","doi-asserted-by":"publisher","first-page":"114118","DOI":"10.1016\/j.jviromet.2021.114118","volume":"292","author":"DM Ejegod","year":"2021","unstructured":"Ejegod DM, Pedersen H, Quint W, Xu L, Arbyn M, Bonde JH. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework. J Virol Methods. 2021;292:114118.","journal-title":"J Virol Methods"},{"key":"2215_CR12","unstructured":"Sundhedsstyrelsen; Screening for livmoderhalskr\u00e6ft - anbefalinger 2012 (in English: The Danish National Board of Health; Cervical cancer screening recommendations 2012). Copenhagen; 2012."},{"key":"2215_CR13","unstructured":"Sundhedsstyrelsen; Screening for livmoderhalskr\u00e6ft - anbefalinger 2018 (in English: The Danish National Board of Health; Cervical cancer screening recommendations 2018). Copenhagen; 2018."},{"issue":"16","key":"2215_CR14","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","volume":"287","author":"D Solomon","year":"2002","unstructured":"Solomon D, Davey D, Kurman R, Moriarty A, O\u2019Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114\u20139.","journal-title":"JAMA"},{"issue":"1","key":"2215_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12879-018-3254-y","volume":"18","author":"M Tranberg","year":"2018","unstructured":"Tranberg M, Jensen JS, Bech BH, Blaak\u00e6r J, Svanholm H, Andersen B. Good concordance of HPV detection between cervico-vaginal self-samples and general practitioner-collected samples using the Cobas 4800 HPV DNA test. BMC Infect Dis. 2018;18(1):348.","journal-title":"BMC Infect Dis"},{"key":"2215_CR16","unstructured":"Statistikbanken (in English: The national bank of statistics): Danmarks Statistik [Available from: https:\/\/www.statistikbanken.dk\/AREALDK."},{"issue":"1","key":"2215_CR17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1186\/s12879-020-05663-7","volume":"20","author":"M Tranberg","year":"2020","unstructured":"Tranberg M, Jensen JS, Bech BH, Andersen B. Urine collection in cervical cancer screening\u2014analytical comparison of two HPV DNA assays. BMC Infect Dis. 2020;20(1):926.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"2215_CR18","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1128\/JCM.01506-12","volume":"50","author":"R van Baars","year":"2012","unstructured":"van Baars R, Bosgraaf RP, ter Harmsel BW, Melchers WJ, Quint WG, Bekkers RL. Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women. J Clin Microbiol. 2012;50(12):3937\u201343.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2215_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/00003081-196712000-00002","volume":"10","author":"RM Richart","year":"1967","unstructured":"Richart RM. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1967;10(4):748\u201384.","journal-title":"Clin Obstet Gynecol"},{"key":"2215_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CLEP.S9908","volume":"2","author":"R Erichsen","year":"2010","unstructured":"Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51\u20136.","journal-title":"Clin Epidemiol"},{"key":"2215_CR21","volume-title":"Practical statistics for medical research","author":"DG Altman","year":"1991","unstructured":"Altman DG. Practical statistics for medical research. Chapman and Hall; 1991."},{"issue":"2","key":"2215_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"2215_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ypmed.2017.05.021","volume":"101","author":"PJW Ketelaars","year":"2017","unstructured":"Ketelaars PJW, Bosgraaf RP, Siebers AG, Massuger L, van der Linden JC, Wauters CAP, et al. High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: results of the VERA study. Prev Med. 2017;101:96\u2013101.","journal-title":"Prev Med"},{"issue":"3","key":"2215_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/cid\/ciab985","volume":"75","author":"T Malag\u00f3n","year":"2022","unstructured":"Malag\u00f3n T, MacCosham A, Burchell AN, El-Zein M, Tellier PP, Coutl\u00e9e F, et al. Proportion of incident genital human papillomavirus detections not attributable to transmission and potentially attributable to latent infections: implications for cervical cancer screening. Clin Infect Dis. 2022;75(3):365\u201371.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2215_CR25","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048\u201356.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2215_CR26","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ijc.27713","volume":"132","author":"WA Tjalma","year":"2013","unstructured":"Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013;132(4):854\u201367.","journal-title":"Int J Cancer"},{"issue":"19","key":"2215_CR27","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/jnci\/djq356","volume":"102","author":"SK Kj\u00e6r","year":"2010","unstructured":"Kj\u00e6r SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical i ntraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478\u201388.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2215_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/rmv.686","volume":"21","author":"CE Schmeink","year":"2011","unstructured":"Schmeink CE, Bekkers RL, Massuger LF, Melchers WJ. The potential role of self- sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol. 2011;21(3):139\u201353.","journal-title":"Rev Med Virol"},{"issue":"10","key":"2215_CR29","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1128\/JCM.00550-17","volume":"55","author":"JUH Lam","year":"2017","unstructured":"Lam JUH, Rebolj M, Ejegod DM, Pedersen H, Rygaard C, Lynge E, et al. Prevalence of human papillomavirus in self-taken samples from screening nonattenders. J Clin Microbiol. 2017;55(10):2913\u201323.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2215_CR30","doi-asserted-by":"publisher","first-page":"e0151978","DOI":"10.1371\/journal.pone.0151978","volume":"11","author":"E Enerly","year":"2016","unstructured":"Enerly E, Bonde J, Schee K, Pedersen H, L\u00f6nnberg S, Nyg\u00e5rd M. Self-sampling for human papillomavirus testing among non-attenders increases attendance to the norwegian cervical cancer screening programme. PLoS ONE. 2016;11(4):e0151978.","journal-title":"PLoS ONE"},{"issue":"1","key":"2215_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12885-020-06888-0","volume":"20","author":"DM Ejegod","year":"2020","unstructured":"Ejegod DM, Lagheden C, Bhatia R, Pedersen H, Boada EA, Sundstr\u00f6m K, et al. Clinical validation of full genotyping CLART\u00ae HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening. BMC Cancer. 2020;20(1):396.","journal-title":"BMC Cancer"},{"issue":"3","key":"2215_CR32","doi-asserted-by":"publisher","first-page":"e0172226","DOI":"10.1371\/journal.pone.0172226","volume":"12","author":"A Del Mistro","year":"2017","unstructured":"Del Mistro A, Frayle H, Rizzi M, Fantin G, Ferro A, Angeletti PM, et al. Methylation analysis and HPV genotyping of self-collected cervical samples from women not responding to screening invitation and review of the literature. PLoS ONE. 2017;12(3):e0172226.","journal-title":"PLoS ONE"},{"issue":"2","key":"2215_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ygyno.2016.02.012","volume":"141","author":"LMA De Strooper","year":"2016","unstructured":"De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HME, van Kemenade FJ, et al. Validation of the FAM19A4\/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV- positive women. Gynecol Oncol. 2016;141(2):341\u20137.","journal-title":"Gynecol Oncol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02215-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:56:22Z","timestamp":1677135382000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02215-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2215"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02215-4","relation":{},"ISSN":["1472-6874"],"issn-type":[{"type":"electronic","value":"1472-6874"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"14 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local Ethical Committee of the Central Denmark Region (journal no.: 1-16-02-209-15) and by the Danish Data Protection Agency (journal no.: 1-10-72-69-15). All participants gave written informed consent to participate in the study. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Danish manufacturer of the Evalyn Brush, Axlab, donated the vaginal self-sampling device for the study but had no influence on the written manuscript. The authors also declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}